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VanillinObjective/Background: Tuberculosis (TB) remains a global threat, claiming one-third of the
population annually. The ever increasing emergence of multidrug-resistant TB (MDR-TB)
is the major impediment to effective anti-TB therapy. Under such circumstances, decipher-
ing the antimycobacterial potential of natural compounds has gained considerable promi-
nence. This study evaluated the antimycobacterial activity of vanillin (Van), a natural food-
flavoring agent and preservative, along with its potential mechanisms of action.
Methods: Drug susceptibilities were performed using broth microdilution, spot, and filter-
disc assays. Membrane damage was studied by nitrocefin hydrolysis and electron micro-
scopy. Virulence attributes were assessed by biofilm formation and cell adherence. Iron
availability was estimated by enzymatic (ferroxidase) assay.
Results: We found that the antimycobacterial activity of Van againstMycobacterium smegma-
tis (a surrogate ofMycobacterium tuberculosis) is 125 lg/mL. Additionally, we observed disrup-
tion of membrane homeostasis in the presence of Van, as revealed by enhanced membrane
permeability and transmission electron microscopy images showing a disturbed cell enve-
lope. Concomitant with our findings, we also observed that Van leads to enhanced drug
susceptibility to membrane targeting known anti-TB drugs. Furthermore, Van affects sig-
nificant virulence traits of Mycobacterium by inhibiting biofilm formation and cell adhe-
sion. Finally, we observed that Van disrupted iron homeostasis as displayed by
hypersensitivity to iron deprivation.
Conclusion: The results established for the first time that Van could be an effective antimy-
cobacterial agent that could be exploited further in treating mycobacterial infections.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).(Manesar)
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Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB)
remains one of the major enemies to humanity. In 2015,
approximately 9.6 million people suffered with TB, of which
1.5 million died [1]. Although TB is generally regarded as a
curable disease, the surplus use of anti-TB drugs has led to
emergence of multidrug-resistant TB (MDR-TB), which occurs
via several mechanisms, including overexpression of drug-
efflux pumps, alteration of membrane permeability, drug
modifications, and target alternation [2]. Therefore, it is extre-
mely pertinent to search for novel and cost-effective regimes
with fewer side effects and superior efficacy over available
drugs. Natural compounds are one of the alternative emerg-
ing approaches that have gained considerable interest for
combating the problem of MDR-TB [3,4].
Among the natural compounds, phenolic derivatives are of
considerable interest basedon their variousproperties, suchas
antimicrobial, antioxidant, anticarcinogenic, antimutagenic,
and anti-inflammatory activities [5]. Several studies reported
the antimycobacterial potential of various phenolic com-
pounds. For example, a lignan phenolic compound,mesodihy-
droguaiaretic acid isolated from Larrea tridentate, inhibits the
alpha subunit of MTB coenzyme A transferase, an enzyme
responsible for both 1- and 2-methylnaphthalene- and
geraniol-degradation pathways [6]. Similarly, chebulic acid
produced by Terminalia chebula is potent to the DNA gyrase
enzyme from wild-type and mutant strains of Mycobacterium
[7]. In previous studies, the antimycobacterial activity of tri-
cyclic diphenol ether engelhardion and 7-methyljuglon was
also reported against MTB [8,9].
Vanillin (Van) is a natural phenolic aldehyde purified from
seed pods of Vanilla planifolia that belong to the Orchidaceae
family. It has a pleasant smell, tastes of vanilla, and is used
asaflavoringagent andaroma in food, beverages, andpharma-
ceuticals. It exhibited antimicrobial activity [10], antioxidant
activity [11,12], hypolipidemic activity [13], and anticarcino-
genic activity [14]. Additionally, somestudies reportedantifun-
gal activity of Van against the medicinally important yeasts
Cryptococcus neoformans and Candida albicans [15]. Furthermore,
the antibacterial effects of Van mixtures with cinnamon and
clove essential oils in controlling Escherichia coli 15:h7 and Liste-
ria monocytogenes in milk were demonstrated [16]; however, no
antimycobacterial activity of Van has been reported.
Here, for the first time, we established the antimycobacte-
rial activity of Van against M. smegmatis, a surrogate of MTB.
We observed that Van administration led to altered cell-
surface integrity and increased susceptibility to known first-
line anti-TB drugs. We also showed the effect of Van on bio-
film formation and adhesion ofM. smegmatis,which aremajor
virulence traits. Van also disturbed iron homeostasis and
DNA-repair mechanisms.
Materials and methods
Materials
Allmedia chemicals, Middlebrook 7H9 broth,Middlebrook 7H10
agar, albumin/dextrose/catalase (ADC), and oleic ADC (OADC)supplements were purchased from BD Biosciences (San Jose,
(INH), and Van were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Ethidium bromide (EtBr), crystal violet, and ferrozine
were purchased from Himedia (Mumbai, India). Dimethyl sul-
foxide (DMSO), potassium chloride (KCl), sodium chloride
(NaCl), disodiumhydrogen orthophosphate (Na2HPO4), potas-
sium dihydrogen orthophosphate (KH2PO4), glycerol, ferrous
sulphate (FeSO4) and ascorbic acid (AA) were obtained from
Thermo Fischer Scientific (Waltham, MA, USA). Methanol was
purchased from Merck (Kenilworth, NJ, USA). Sodium acetate
waspurchased fromQualigens FineChemicals (Mumbai, India).
Bacterial strains and culture conditions
M. smegmatis mc2155 was grown in Middlebrook 7H9 (BD Bio-
sciences) broth supplemented with 0.05% Tween-80 (Sigma-
Aldrich), 10% ADC (BD Biosciences), and 0.2% glycerol
(Thermo Fischer Scientific) in 100-mL flasks and incubated
at 37 C. Cultures were subsequently grown on Middlebrook
7H10 (BD Biosciences) agar media supplemented with 10%
(v/v) OADC (BD Biosciences) for solid agar allowing growth
for 48 h at 37 C. Stock cultures of log-phase cells were main-
tained in 30% glycerol and stored at 80 C.
Drug-susceptibility testing
Minimum inhibitory concentration
Minimum inhibitory concentration (MIC) was determined using
the broth-dilution method described previously [17] according
to Clinical and Laboratory Standards Institute guidelines [18].
Briefly, 100 lL of Middlebrook 7H9 broth was placed in each well
of a 96-well plate, followed by the addition of the drug with the
remainingmediaandsubsequent serial dilution.Cell suspension
(100 lL in normal saline at an optical density at 600 nm [OD600] of
0.1) was added to each well, followed by incubation at 37 C
for 48 h. The MIC (Genetix, Biotech Asia Pvt. Ltd.) values were
evaluated by observing the OD600 in a microplate reader.
Spot assay
Spot assays for the strains were determined using a method
described previously [17]. Briefly, 5 lL of fivefold serial dilu-
tions of each M. smegmatis culture (each with cells suspended
in normal saline to an OD600 of 0.1) was spotted onto Middle-
brook 7H10 agar plates in the absence (control) or presence of
the drugs. Growth difference was measured after incubation
at 37 C for 48 h.
Filter-disc assay
The filter-disc assay was performed as described previously
[17]. The drugswere spotted in a volume of 5–10 lL at the indi-
cated concentrations, and the diameters of the respective
zones of inhibition were measured after incubation of the
plates for 48 h at 37 C.
Membrane-permeability assay
The b-lactamase activity associated with the permeabiliza-
tion of M. smegmatis was determined by measuring the
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[17]. Briefly, cells were grown overnight at 37 C in the absence
(control) or presence of Van at its subinhibitory concentration
with continuous shaking. Cells were then equilibrated with
cold 1 phosphate buffered saline (PBS; pH 7.4). Nitrocefin
was added to a final concentration of 0.25 mg/mL to the ali-
quot of cells (2 mL) in 1 PBS (pH 7.4), and hydrolysis was
monitored at 485 nm for 60 min using a double-beam spec-
trophotometer (VSI-501; VSI Electronics, Punjab, India).
Transmission electron microscopy
Treated and untreated cells of M. smegmatis were observed
using transmission electron microscopy (TEM: JEOL JEM-
1011; JEOL, Delhi, India). Cells at an OD600 of 0.1 were seeded
to the media in the absence (control) and presence of Van
and incubated for 24 h at 37 C. Sample preparation and anal-
ysis were performed using previously described methods [17].
Briefly, cells were harvested in PBS, fixedwith 2.5% glutaralde-
hyde in 0.1% phosphate buffer for 1 h at room temperature
(20 C), washedwith 0.1 M phosphate buffer (pH 7.2), and post-
fixed with 1% Osmium tetroxide (OsO4) in 0.1 M phosphate
buffer for 1 h. Cells were then dehydrated with ethanol, dried
and coated with gold, and observed at a magnification of
10,000.
Biofilm formation
M. smegmatis biofilm-forming potential was qualitatively and
quantitatively analyzed using the microtiter-plate method as
described previously, with some modifications [19,20]. Briefly,
M. smegmatis cultureswere grown overnight at 37 C inMiddle-
brookmedia, followedby transferof 100 lLof themedia ineach
well of the 96-well plate with or without the addition of the
drug. Cultures that had reached an OD600 of 0.1 were diluted
(1:100) using Middlebrook media, and 100 lL of each diluted
culture was pipetted into each well of a 96-well flat-bottom
microtiter plate and incubated at 37 C for 48 h. Thewellswere
rinsedwithwater, and125 lL of 0.1%solutionof the crystal vio-
let was added. Plates were incubated for 10 min, followed by
washing with distilled H2O three times and observation under
a light microscope at 100. For quantitative assays of the bio-
film, 200 lL of 95% ethanol was added to each crystal violet-
stained well, and plates were incubated for 10 min at room
temperature. Contents of each well were mixed by pipetting,
followedby transfer of 125 lL of the crystal violet/ethanol solu-
tion from eachwell to a separatewell of an optically clear flat-
bottom 96-well plate. The OD600 was measured using a spec-
trophotometer. The antibiofilm capability of Van-treated cells
was measured as percentage of inhibition/reduction. For the
cell-adhesion assay, the same procedure was followed, except
that treated and untreated cells were grown to an OD600 of 1.0,
and after washing the nonadhered cells, they were directly
quantified using crystal violet staining.
Adherence of Mycobacterium on human buccal epithelial cells
The cell-adherence assaysweremodified from previousmeth-
ods [21,22]. Epithelial cells were obtained from the mouth cav-
ity of healthy people and washed two to three times with PBSby centrifugation at 1048 x g for 5 min at 4 C. The pellets
were then resuspended in PBS to obtain an OD600 of approxi-
mately 0.5. Bacterial cells were grown in Middlebrook 7H9
broth in the presence or absence of Van at subinhibitory con-
centrations (15 lg/mL) and incubated overnight at 37 C. The
culture was adjusted to allow for absorbance at 650 nm of
approximately 0.5. The bacteria were then washed twice in
PBS and centrifuged for 10 min at 10,000 rpmand resuspended
in PBS. The test was performed by taking equal volumes of
buccal epithelial cells (OD600 = 0.5) and bacterial suspensions
that were mixed and incubated with shaking (120 rpm) at
37 C for 2–3 h. After incubation, two drops of trypan blue solu-
tion (0.4%) and carbol fuchsin (3–5 mL) were added to each tube,
and the mixture was gently shaken. The stained suspension
(10 lL) was transferred to a Neubauer chamber and examined
under light microscopy.
Ferroxidase assay
Whole-cell protein was extracted, and protein concentration
was determined using the Lowry method in preparation for
the ferroxidase assay according to a method previously
described [23,24]. Bacterial cells were grown in Middlebrook
7H9 broth in the presence or absence of Van at subinhibitory
concentrations (15 lg/mL). The assay was performed using
ferrous sulphate as the electron donor and 3-(2-pyridyl)-5,6-
bis(4-phenylsulfonic acid)-1,2,4-triazine (ferrozine) as a chela-
tor to specifically detect the ferrous iron remaining at the end
of the reaction. Each assay mixture (0.2 mL) contained 50 mM
Na-acetate buffer (pH 5) and 0.1–0.3 lg of protein extract. The
reaction was started by addition of 0.2 mM FeSO4, and sam-
ples were quenched by adding 3.75 mM ferrozine. Fe(II) oxida-
tion was determined by measuring the absorbance of residual
Fe(II)-ferrozine at 570 nm.
Results
Antimycobacterial activity of Van
To detect the antimycobacterial activity of Van, three inde-
pendent types of drug-susceptibility assay, including mea-
surement of MIC using the broth-dilution method, spot
assay, and filter-disc assay, were performed. The broth-
dilution method revealed that Van showed antimycobacterial
activity againstM. smegmatis at 125 lg/mL (Fig. 1A). This result
was further confirmed by performing spot assays (Fig. 1B) and
filter-disc assays (Fig. 1C). All the susceptibility tests corre-
lated with each other, and it was observed thatMycobacterium
showed susceptibility to Van at a concentration of 125 lg/mL.
Assessment of growth following Van treatment
For subsequent biochemical assays and to study the effects of
Van treatment, we needed to determine a subinhibitory con-
centration of Van that would affect normal cellular functions
of Mycobacterium without causing cell death. To address this
issue, growth curves were obtained in the absence (control)
and presence of Van, and we observed that growth was par-
tially affected at 15 lg/mL Van (Fig. 2A). To confirm the above
concentration, a spot assay was performed using 15 lg/mL
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Fig. 1 – Antimycobacterial activity of Van against Mycobacterium smegmatis. (A) Broth-microdilution assay to determine the
MIC80 of M. smegmatis in the presence of Van. (B) Spot assay of M. smegmatis in the absence (control) or presence of Van
(125 lg/mL). (C) Filter-disc assay against and their zone of inhibition in the absence (control) or presence of Van (125 lg/mL).
Discs were spotted with solvent (DMSO) as control. Note: DMSO, dimethyl sulfoxide; MIC, minimum inhibitory concentration;
Van, vanillin.
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Fig. 2 – Assessment of growth in the presence of Van. (A)
Growth curve of Mycobacterium smegmatis in the absence
(control) or presence of Van (15 lg/mL). (B) Spot assay of M.
smegmatis in the absence (control) or the presence of
subinhibitory concentrations of Van (15 lg/mL). Note: Van,
vanillin.
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(Fig. 2B). Therefore, we selected 15 lg/mL as the subinhibitory
Van concentration for further experiments.Effect of Van on cell-surface integrity
To study the effects of Van treatment on membrane integrity,
we performed a membrane-permeability assay. Our results
showed enhanced membrane permeability due to hydrolysis
of nitrocefin in the presence of Van compared with
permeability measured in untreated cells (control), indicating
distortion of the M. smegmatis membrane (Fig. 3A). Disrupted
membrane integrity was further observed by TEM, which
clearly showed that Van disrupted the M. smegmatis cell
envelope (Fig. 3B). Furthermore, we also tested the effects of
Van in combination with known anti-TB drugs, including
INH and EMB, which target membranes. We performed a
broth-microdilution assay and observed that the drug-
susceptibility associated with both of the anti-TB drugs (INH
and EMB) was enhanced (from 4 lg/mL to 1 lg/mL for INH,
and from 0.25 lg/mL to 62.5 ng/mL for EMB) in the presence
of Van (Fig. 3C).
Effect of Van virulence attributes
Van inhibits biofilm formation
To study the effects of Van treatment on biofilm formation in
M. smegmatis, we performed a biofilm-formation assay using
qualitative and quantitative methods involving crystal violet
dye. For qualitative testing, biofilm was visualized by staining
control and Van-treated biofilms with crystal violet dye and
observing considerable reduction in biofilm formation in the
Van-treated samples (Fig. 4A). This result was validated by
quantitative analysis through solubilizing the stained crystal
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Fig. 3 – Effect of Van treatment on cell-surface integrity. (A) Membrane-permeability assay for Mycobacterium smegmatis cells
grown in the absence (control) or the presence of Van (15 lg/mL). Mean of OD485 ± SD of three independent experiments are
depicted on the Y-axis with respect to time (min) on X-axis (p < .05). (B) Transmission electron micrograph images of M.
smegmatis cells grown in the absence (control) or presence of Van (125 lg/mL), showing disruption of membrane integrity. (C)
Broth-microdilution assay of M. smegmatis with known anti-TB drugs (INH and EMB) in the presence of Van. Data were
quantitatively displayed with color (see color bar), where each shade of color represents relative optical densities of the cell.
The minimum drug concentration that inhibits growth by 80% relative to the drug-free growth control is indicated as MIC80.
Note: Conc., concentration; EMB, ethambutol; INH, isoniazid; MIC, minimum inhibitory concentration; OD, optical density; SD,
standard deviation; Van, vanillin.
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600 nm, which confirmed that biofilm formation was signifi-
cantly inhibited (64.96%) in the presence of Van relative to bio-
film formation observed in control (Fig. 4B).
Van inhibits cell adherence to polystyrene and buccal epithelial
cells
We tested the effects of Van treatment on cell adherence to
both polystyrene and human epithelial cells. We observed
that Van treatment resulted in diminished cell adherence of
M. smegmatis on polystyrene microtiter surfaces (Fig. 4C).
Interestingly, we also observed that Van treatment inhibited
adherence of Mycobacterium on buccal epithelial cells com-
pared with adherence on untreated cells (Fig. 4D).
Van disrupts iron homeostasis
We then assessed the effects of Van treatment on iron avail-
ability. We performed spot assays with ferrozine, which is
an iron chelator, and observed that M. smegmatis were hyper-
sensitive in presence of Van to iron deprivation as compared
with control cells (Fig. 5A). To confirm this observation, weperformed a ferroxidase enzymatic assay to estimate the
nonoxidized ferrous iron present in the reaction mixture. As
expected, we found significantly reduced ferroxidase activity
byM. smegmatis, suggesting that free iron levels were reduced
in the presence of Van (Fig. 5B). Furthermore, we investigated
the effects of Van treatment under alkaline pH conditions by
performing a spot assay. Unexpectedly, we observed no differ-
ence in the growth of M. smegmatis at alkaline pH compared
with that observed at physiological pH, even in the presence
of Van (Fig. 5C).
Effects of Van treatment on genotoxicity and redox status
We determined whether the antimycobacterial mechanisms
associated with Van are also associated with effects on DNA
repair. We performed spot assays on M. smegmatis using EtBr,
which is a known DNA-damaging agent, at concentrations
that resulted in no appreciable growth defects. We observed
that Van treatment exhibited a moderate effect on DNA-
repair mechanisms, as cells were susceptible to damage
resulting from EtBr administration (Fig. 6A). Furthermore,
we assessed whether the observed genotoxicity due to Van
BA
Control Van
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
Control Van
O
D
60
0
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
Control Van
O
D
60
0
*
*
DC
50µm 50µm
Control Van
Fig. 4 – Effect of Van treatment on virulence traits ofMycobacterium smegmatis. (A) Crystal violet staining showing the biofilm
formation in the absence (control) and presence of Van (15 lg/mL). (B) Effect of Van (15 lg/mL) on biofilm formation of M.
smegmatis depicted as a bar graph and quantified using crystal violet dye. Mean OD600 ± SD of three independent
experiments are depicted on the Y-axis. (C) Effect of Van (15 lg/mL) on cell adhesion on microtiter polystyrene surface of M.
smegmatis quantified using crystal violet dye. Mean OD600 ± SD of three independent experiments are depicted on the Y-axis.
(D) Effect of Van (15 lg/mL) on cell adherence of M. smegmatis with human oral epithelial cells. Left panel depicts untreated
cells adhered to human buccal epithelial cells and right panel depicts Van-treated (15 lg/mL) M. smegmatis cells not adhered
to epithelial cells. Note: OD, optical density; SD, standard deviation; Van, vanillin. *p < .05.
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states. We performed a spot assay in the presence of a known
antioxidant (ascorbic acid) and observed that cells were
hypersensitive to Van treatment when grown at MIC80; how-
ever, this hypersensitivity could not be rescued, even upon
supplementation with the antioxidant (Fig. 6B).
Discussion
In the era of increasing MDR-TB burden, discovery of novel
antimycobacterial compounds preferably from natural
sources due to their safety profiles has become a renewed
source of interest. This study aimed to establish the antimy-
cobacterial activity of Van, a natural food-flavoring agent,
against M. smegmatis, a surrogate of MTB. All three indepen-
dent methods of measuring drug susceptibility confirmed
that Van exhibited antimycobacterial activity at 125 lg/mL.
Deeper insights into the possible modes of action revealed
multiple targets for Van.
Mycobacterium contains unique cell-surface architectures
comprised of peptidoglycan attached to arabinogalactan,
which is covalently linked to mycolic acid. The mycolic acids
are the main components of mycobacterial cell walls and
attractive targets of many anti-TB drugs. Moreover, severalnatural compounds were reported to possess antimycobac-
terial activity against Mycobacterium through membrane
targeting. Epigallocatecin gallate is a compound found in
green-tea extract and is capable of damaging the cell wall
in M. smegmatis [25]. Similarly, another study showed three
compounds, butein, isoliquirtigenin, and 2,20,40-trihydroxy
chalcone, derived from Rhus verniciflua and Dalbergia odor-
ifera, respectively, which inhibit mycolic acid biosynthesis
in MTB [26]. Therefore, we investigated the effect of
Van treatment on membrane integrity using different
methods.
First, we performed membrane-permeability assays using
nitrocefin, a chromogenic cephalosporin substrate containing
an amide bond in the b-lactam ring, which is hydrolyzed by b-
lactamase, normally localized to the bacterial periplasm.
Membrane permeability was considerably enhanced in pres-
ence of Van (Fig. 3A). Similarly, TEM images revealed that
Van disrupted the cell envelope of M. smegmatis (Fig. 3B). To
substantiate the membrane- perturbing effects, we tested
the effects of Van treatment in combination with known
membrane-targeting anti-TB drugs INH and EMB. Enhanced
drug susceptibilities for both the tested drugs in presence of
Van (Fig. 3C) reinforced our findings that Van targeted the
membrane integrity of M. smegmatis.
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Fig. 5 – Effects of Van treatment on iron homeostasis. (A) Spot assay of Mycobacterium smegmatiswith iron chelator ferrozine
(2.5 mM) in the absence (control) or presence of Van (15 lg/mL). (B) Effect of Van treatment (15 lg/mL) on iron availability inM.
smegmatis depicted as a bar graph and quantified by ferroxidase assay. Mean OD570 ± SD of three independent experiments
are depicted on the Y-axis. (C) Spot assay of M. smegmatis in the absence (control) or presence of Van (15 lg/mL) at
physiological and alkaline pH 10. Note: OD, optical density; SD, standard deviation; Van, vanillin. *p < .05.
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Fig. 6 – Effect of Van treatment on genotoxicity and redox status of Mycobacterium smegmatis. (A) Spot assay showing
hypersensitivity of M. smegmatis to Van treatment (15 lg/mL) in the presence of EtBr (4 lg/mL), a DNA-damaging agent. (B)
Spot assay demonstrating hypersensitivity of M. smegmatis in the presence of Van (MIC80) that could not be reversed
following addition of the antioxidant ascorbic acid (5 mM). AA, ascorbic acid; EtBr, ethidium bromide; MIC, minimum
inhibitory concentration; Van, vanillin.
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the cell surface through extracellular polymeric substances.
This is a major virulence factor that contributes to resistance
against various antimycobacterial drugs. Further, inhibited
biofilm formation (Fig. 4A and B) led us to examine the effects
of Van treatment on cell adherence, because it is the primary
step for biofilm formation. Interestingly, we observed that Van
treatment diminished M. smegmatis cell adherence to poly-
styrene microtiter surfaces (Fig. 4C). We subsequently verified
these results using human buccal epithelial cells. For the
infection process, bacterial pathogens express various mole-
cules capable of promoting attachment of bacteria to host
epithelial cells. The adhesion molecules interact withhost-cell receptors or soluble proteins, thereby acting as a link
between the bacteria and the host. Therefore, this is a critical
step prior to invasion and pathogenesis. We observed that
Van treatment inhibited the adherence of Mycobacterium on
epithelial cells compared with untreated cells (Fig. 4D). These
results confirmed that Van is a potent inhibitor of virulence
attributes associated with M. smegmatis, resulting in inhibi-
tion of biofilm formation and cell adherence.
Iron is a metal essential for the survival of living organ-
isms, including Mycobacterium. It is essential for the activity
of different enzymes involved in wide ranges of metabolic
processes, including DNA synthesis and cell respiration. The
availability of free iron in the mammalian host is extremely
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 4 6 0 –4 6 8 467low; therefore, Mycobacterium compete with the host for lim-
ited iron to establish successful infection. Our group previ-
ously reported that iron deprivation affects susceptibility of
Mycobacterium to known anti-TB drugs, and that iron avail-
ability is a key factor in considering antimycobacterial drug
susceptibilities [17,27]. Moreover, we established that Van
treatment hinders iron homeostasis in other prevalent
human fungal pathogens, such as Candida albicans (unpub-
lished data). The above findings necessitated to study the
effects of Van treatment on iron homeostasis in Mycobac-
terium, revealing that Van treatment disrupted iron home-
ostasis (Fig. 5A and B).
Alkaline pH also mimics iron deprived condition [17]. In
the body, iron exists in two states: insoluble Fe(III) and soluble
Fe(II). In the case of alkaline pH, iron is predominantly present
in the insoluble form, thereby representing an iron-deprived
condition [28]. Moreover, when Mycobacterium infects
humans, it encounters anatomically diverse niches that
include alkaline-pH environments. Therefore, we studied
the effect of Van treatment at alkaline pH; however, we
observed no difference in the growth of M. smegmatis at alka-
line pH compared with that observed at physiological pH,
even in the presence of Van (Fig. 5C). This suggests that Van
specifically targeted iron and not pH-dependent pathways in
Mycobacterium.
During the course of infection through inhalation,
Mycobacterium encounter alveolar macrophages in the lungs.
Macrophages are phagocytic cells involved in the production
of reactive oxygen and nitrogen species during phagocytosis
or stimulation with various agents. Macrophages can cause
different types of DNA damage, including oxidation, depuri-
nation, deamination, and methylation, which are responsible
for single- and double-strand breaks [29]. In our study, we
confirmed that antimycobacterial mechanisms associated
with Van were also associated with effects on DNA repair
(Fig. 6A). We also determined that genotoxicity following
Van treatment was not associated with any alterations in
the redox state of the cell (Fig. 6B), ruling out the possibility
that antimycobacterial mechanisms associated with Van
treatment involved Reactive Oxygen Species (ROS) produc-
tion. However, further studies are needed to validate the
above hypothesis.
Conclusion
Natural compounds, such as Van, that may be used as
antimycobacterial drugs to overcome MDR-TB have become
emerging sources of interest. Our results suggested that Van
is active against Mycobacterium and could be a promising can-
didate for the development of new antimycobacterial agents.
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